Regular ArticleXenogeneic DNA Immunization in Melanoma Models for Minimal Residual Disease☆
References (11)
- et al.
Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity
Surgery
(2000) - et al.
Tumor immunity and autoimmunity induced by immunization with homologous DNA
J. Clin. Invest.
(1998) - et al.
Coupling and uncoupling of tumor immunity and autoimmunity
J. Exp. Med.
(1999) - et al.
T cell-mediated suppression of the concomitant antitumor immune response as an example of transplantation tolerance
Transplant. Proc.
(1984) - et al.
Injection of DNA encoding granulocyte–macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects
Cytokines Cell. Mol. Ther.
(1999)
Cited by (38)
Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice
2011, VaccineCitation Excerpt :Pre-clinical data indicate that trastuzumab resistance results from co-expression of growth factor receptors (EGFR family, IGF-1 R) and activation of the PI3K-Akt pathway (mainly by loss of PTEN function) [4]. We have previously made use of direct immunization with xenogeneic DNA vaccines in animal models of cancer [5–7]. Xenogeneic DNA vaccines have shown efficacy in pre-clinical mouse studies.
Construction of a triple modified p53 containing DNA vaccine to enhance processing and presentation of the p53 antigen
2009, VaccineCitation Excerpt :Recently xenogeneic antigens administered as DNA vaccine intramuscular were found to induce an immune response to melanoma in dogs [24]. Protection against murine glioma and melanoma was found after co-stimulation with xenogeneic but related antigens [25,26]. Following the xenogeneic approach epitope and antigen spreading [27] has been held responsible for the positive effect, however the precise mechanism and the relation between “target”antigen and adjuvant is less clear.
Xenovaccinotherapy for colorectal cancer
2007, Biomedicine and PharmacotherapyCitation Excerpt :Although both autologous and allogeneic cell vaccines are well studied, we favor a xenogenic vaccine. Evidence has been accumulated to demonstrate that the xenogenic TAAs can be much more effective in eliciting antitumor immune responses than their homological analogs [5–9]. The vaccine under study is composed of disrupted murine B16 melanoma and LLC carcinoma cells.
Immunotherapy of Melanoma
2006, Hematology/Oncology Clinics of North AmericaTransduction of the gene coding for a human G-protein coupled receptor FPRL1 in mouse tumor cells increases host anti-tumor immunity
2005, International Immunopharmacology
- ☆
Abbreviation used: hTRP2, human-tyrosinase-related peptide-2.